Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | EML4 - ALK KEAP1 dec exp |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| EML4 - ALK KEAP1 dec exp | lung cancer | sensitive | Crizotinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Xalkori (crizotinib) in a lung cancer cell line and patient-derived lung cancer cells harboring EML4-ALK in culture (PMID: 28145866). | 28145866 | |
| EML4 - ALK KEAP1 dec exp | lung cancer | decreased response | Ceritinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Zykadia (ceritinib) in patient-derived lung cancer cells harboring EML4-ALK in culture (PMID: 28145866). | 28145866 |